ResearchPod Summary
Agitation and aggression are common, distressing, and costly symptoms of Alzheimer's dementia (AD) that often lead to early institutionalization. Current pharmacological treatments, such as antipsychotics and benzodiazepines, are frequently associated with significant side effects and limited efficacy. This study, the 'Sativex for Agitation & Aggression in Alzheimer’s Dementia' (STAND) trial, investigated the feasibility and safety of using nabiximols—an oromucosal spray containing a 1:1 ratio of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)—as a potential alternative treatment for these symptoms in UK nursing home residents.
The researchers conducted a randomized, double-blind, placebo-controlled feasibility trial. Participants with probable AD and clinically significant agitation were randomized to receive either the nabiximols spray or a placebo over a 4-week up-titration period, followed by a 4-week observation phase. The study aimed to meet specific feasibility thresholds, including recruiting 60 participants within 12 months, achieving high retention (≥75%) and adherence (≥80%), and estimating a minimum effect size (Cohen's d ≥ 0.3) on the Cohen-Mansfield Agitation Inventory (CMAI).
Despite significant disruptions caused by the COVID-19 pandemic, the trial successfully demonstrated that the intervention is feasible and safe. While the study did not meet its full recruitment target (29 participants were randomized), it achieved 100% retention and 100% adherence among those enrolled. The intervention was well-tolerated with no adverse reactions or safety concerns reported, suggesting that the oromucosal delivery route—which bypasses the gastrointestinal tract—is a viable method for this vulnerable population. Although the study was not powered to determine efficacy, the preliminary data on agitation scores did not reach the prespecified effect size threshold, indicating that further research is needed to establish therapeutic benefit.
This study provides a critical foundation for future research into cannabinoid-based therapies for dementia. By demonstrating that nabiximols can be safely administered in a frail, late-stage dementia cohort, the researchers have cleared the path for larger, phase-III confirmatory trials. The findings suggest that future studies should focus on dose-finding and potentially include community-dwelling participants to improve recruitment and generalizability.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.